JP7687699B2 - リン酸化タウタンパク質を標的とする免疫原性組成物 - Google Patents

リン酸化タウタンパク質を標的とする免疫原性組成物 Download PDF

Info

Publication number
JP7687699B2
JP7687699B2 JP2022547604A JP2022547604A JP7687699B2 JP 7687699 B2 JP7687699 B2 JP 7687699B2 JP 2022547604 A JP2022547604 A JP 2022547604A JP 2022547604 A JP2022547604 A JP 2022547604A JP 7687699 B2 JP7687699 B2 JP 7687699B2
Authority
JP
Japan
Prior art keywords
tau
phosphorylated
protein
tau protein
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022547604A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022054795A1 (enrdf_load_stackoverflow
Inventor
啓徳 中神
竜一 森下
朱公 武田
宏樹 林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka University NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of JPWO2022054795A1 publication Critical patent/JPWO2022054795A1/ja
Priority to JP2024202001A priority Critical patent/JP2025020455A/ja
Application granted granted Critical
Publication of JP7687699B2 publication Critical patent/JP7687699B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022547604A 2020-09-08 2021-09-07 リン酸化タウタンパク質を標的とする免疫原性組成物 Active JP7687699B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024202001A JP2025020455A (ja) 2020-09-08 2024-11-20 リン酸化タウタンパク質を標的とする免疫原性組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020150890 2020-09-08
JP2020150890 2020-09-08
PCT/JP2021/032847 WO2022054795A1 (ja) 2020-09-08 2021-09-07 リン酸化タウタンパク質を標的とする免疫原性組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024202001A Division JP2025020455A (ja) 2020-09-08 2024-11-20 リン酸化タウタンパク質を標的とする免疫原性組成物

Publications (2)

Publication Number Publication Date
JPWO2022054795A1 JPWO2022054795A1 (enrdf_load_stackoverflow) 2022-03-17
JP7687699B2 true JP7687699B2 (ja) 2025-06-03

Family

ID=80632171

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547604A Active JP7687699B2 (ja) 2020-09-08 2021-09-07 リン酸化タウタンパク質を標的とする免疫原性組成物
JP2024202001A Pending JP2025020455A (ja) 2020-09-08 2024-11-20 リン酸化タウタンパク質を標的とする免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024202001A Pending JP2025020455A (ja) 2020-09-08 2024-11-20 リン酸化タウタンパク質を標的とする免疫原性組成物

Country Status (4)

Country Link
US (1) US20230310561A1 (enrdf_load_stackoverflow)
EP (1) EP4212172A4 (enrdf_load_stackoverflow)
JP (2) JP7687699B2 (enrdf_load_stackoverflow)
WO (1) WO2022054795A1 (enrdf_load_stackoverflow)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032675B1 (ru) * 2009-06-10 2019-07-31 Нью-Йорк Юниверсити Способ и композиции для лечения болезни альцгеймера и других таупатий
IL273980B2 (en) * 2017-10-25 2025-02-01 Janssen Pharmaceuticals Inc Phosphorylated tau peptide preparations and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIERNAT J. et al.，The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine- pro，The EMBO Journal，1992年，Vol. 11 No.4，p.1593-1597，ISSN:0261-4189
KLAVER Andrea C. et al.，Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impa，Translational Neurodegeneration，2017年，Vol.6 No.1，Article.32 (p.1-9)，ISSN:2047-9158
LEBOUVIER Thibaud et al.，The microtubule-associated protein tau is phosphorylated by Syk，Biochimica et Biophysica Acta，2008年，Vol.1783 No.2，p.188-192，ISSN:0005-2728
SUBRAMANIAN Sarada, et al.，Passive immunization targeting the N-terminal region of phosphorylated tau (residues 68-71) improves，Biochemical and Biophysical Research Communications，2017年，Vol.483 No.1，p.585-589，ISSN:0006-291X
中神啓徳、森下竜一，特集 温故知新の医療技術「ワクチン」 ６ 認知症・生活習慣病を標的とした治療ワクチン，アンチ・エイジング医学－日本抗加齢医学会雑誌，2019年，Vol.15 No.1，p.55-59
武田朱公，病的タウの神経細胞間伝播を標的とした認知症治療法の開発，平成30年度精神薬療分野若手研究者継続助成研究成果報告書，2019年，p.70-71

Also Published As

Publication number Publication date
WO2022054795A1 (ja) 2022-03-17
EP4212172A4 (en) 2024-10-16
JP2025020455A (ja) 2025-02-12
EP4212172A1 (en) 2023-07-19
US20230310561A1 (en) 2023-10-05
JPWO2022054795A1 (enrdf_load_stackoverflow) 2022-03-17

Similar Documents

Publication Publication Date Title
Klyubin et al. Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
ES2549070T3 (es) Prevención y tratamiento de una enfermedad sinucleinopática
EP2450056B1 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
US8778343B2 (en) Antibodies that bind tau oligomers
US11919947B2 (en) Antibody binding active α-synuclein
US9895429B2 (en) Antibodies that bind amyloid oligomers
US8940306B2 (en) Method for enhancing immune response with peptide
JP5559789B2 (ja) アルツハイマー病の処置のための免疫治療組成物
CN102946899A (zh) 药物组合物
JP2011522842A (ja) パーキンソン病に関連する症状の治療のための化合物
US8512709B2 (en) Modified amyloid β peptide
ES2727407T3 (es) Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
JPWO2018155457A1 (ja) Ｓ１００ａ９を標的とする免疫原性組成物
JP7687699B2 (ja) リン酸化タウタンパク質を標的とする免疫原性組成物
Vingtdeux et al. A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides
US9770496B2 (en) Method for treating amyloid disease
US20240358806A1 (en) Methods for the prevention and treatment of synucleinopathies
US11046746B2 (en) Method of treatment of cerebral amyloid angiopathy with P75ECD peptide and/or P75ECD-FC fusion protein
ES2625606T3 (es) Prevención y tratamiento de la enfermedad sinucleinopatía y amiloide
BR112017026948B1 (pt) Composição imunogênica que compreende gmma de shigella, e seu uso
HK1127486B (zh) 治疗性疫苗
HK1127486A1 (en) Therapeutic vaccine

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250515

R150 Certificate of patent or registration of utility model

Ref document number: 7687699

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150